HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim- sulfamethoxazole inhibit plasmodium liver stages

Journal of Infectious Diseases

Volumn 206, Issue 11, 2012, Pages 1706-1714

  Hobbs, Charlotte V ^a   Voza, Tatiana ^b   De La Vega, Patricia ^c   Vanvliet, Jillian ^a   Conteh, Solomon ^a   Penzak, Scott R ^d   Fay, Michael P ^a   Anders, Nicole ^e   Ilmet, Tiina ^f   Li, Yonghua ^f   Borkowsky, William ^f   Krzych, Urszula ^c   Duffy, Patrick E ^a   Sinnis, Photini ^g  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NEW YORK CITY COLLEGE OF TECHNOLOGY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER; MALARIA FALCIPARUM; MEROZOITE; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; SPOROZOITE;

ANIMALS; ANTIMALARIALS; FEMALE; HUMANS; LIVER; MALARIA; MICE; PARASITEMIA; PLASMODIUM; REVERSE TRANSCRIPTASE INHIBITORS; SPECIES SPECIFICITY; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84869030227     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis602     Document Type: Article

References (50)

1. Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis 2011; 11:541-56.
2. Hobbs CV, Voza T, Coppi A, et al. HIV protease inhibitors inhibit the development of preerythrocytic-stage Plasmodium parasites. J Infect Dis 2009; 199:134-41.
3. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. http://whqlibdoc.who.int/publications/2010/97892415 99764-eng.pdf. Accessed 1 March 2012.
4. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access, recommendations for a public health approach. http://whqlibdoc.who.int/publications/2010/9789241599801-eng.pdf. Accessed 1 March 2012.
5. WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents, and adults: recommendations for a public health approach. http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf. Accessed 1 March 2012.
6. WHO. Co-trimoxazole prophylaxis for HIV-exposed and HIV-infected infants and children: practical approaches to implementation and scale-up. http://www.who.int/hiv/pub/paediatric/cotrimoxazole.pdf. Accessed 1 March 2012.
7. Ejigiri I, Sinnis P. Plasmodium sporozoite-host interactions from the dermis to the hepatocyte. Curr Opin Microbiol 2009; 12:401-7.
8. Food and Drug Administration (FDA). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm07 8932.pdf. Accessed 14 February 2012.
9. De Jonghe S, Verbeeck J, Vinken P, et al. Hemorrhagic cardiomyopathy in male mice treated with an NNRTI: the role of vitamin K. Toxicol Pathol 2008; 36:321-9.
10. Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009; 48:1123-8.
11. Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the nonnucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther 2010; 88:695-703.
12. Stoddart CA, Bales CA, Bare JC, et al. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PloS One 2007; 2:e655.
13. Streck EL, Scaini G, Rezin GT, Moreira J, Fochesato CM, Romao PR. Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metab Brain Dis 2008; 23:485-92.
14. Tohyama J, Billheimer JT, Fuki IV, Rothblat GH, Rader DJ, Millar JS. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis 2009; 204:418-23.
15. Alonso Campero R, Bernardo Escudero R, Del Cisne Valle Alvarez D, et al. Bioequivalence of two commercial preparations of trimethoprim/sulfamethoxazole: a randomized, single-dose, single-blind, crossover trial. Clin Ther 2007; 29:326-33.
16. Altholtz LY, La Perle KM, Quimby FW. Dose-dependant hypothyroidism in mice induced by commercial trimethoprim-sulfamethoxazole rodent feed. Comp Med 2006; 56:395-401.
17. Freund YR, Dousman L, MacGregor JT, Mohagheghpour N. Oral treatment with trimethoprim-sulfamethoxazole and zidovudine suppresses murine accessory cell-dependent immune responses. Toxicol Sci 2000; 55:335-42.
18. Zar HJ, Langdon G, Apolles P, Eley B, Hussey G, Smith P. Oral trimethoprim- sulphamethoxazole levels in stable HIV-infected children. S Afr Med J 2006; 96:627-9.
19. FDA. Guidance for industry: bioanalytical method validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf. Accessed 20 March 2012.
20. Killick-Kendrick R, Peters W. Rodent Malaria. New York: Academic press, 1978.
21. Bruna-Romero O, Hafalla JC, Gonzalez-Aseguinolaza G, Sano G, Tsuji M, Zavala F. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 2001; 31:1499-502.
22. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, Omura S, Nussenzweig V, Sinnis P. Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother 1998; 42:2731-8.
23. Yamauchi LM, Coppi A, Snounou G, Sinnis P. Plasmodium sporozoites trickle out of the injection site. Cell Microbiol 2007; 9:1215-22.
24. Sinden RE, Suhrbier A, Davies CS, Fleck SL, Hodivala K, Nicholas JC. The development and routine application of high-density exoerythrocytic- stage cultures of Plasmodium berghei. Bull World Health Organ 1990; 68 (Suppl):115-25.
25. VanBuskirk KM, O'Neill MT, De La Vega P, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A 2009; 106:13004-9.
26. Sattabongkot J, Yimamnuaychoke N, Leelaudomlipi S, et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. AmJ TropMed Hyg 2006; 74:708-15.
27. Ozaki LS, Gwadz RW, Godson GN. Simple centrifugation method for rapid separation of sporozoites from mosquitoes. J Parasitol 1984; 70:831-3.
28. Tsuji M, Mattei D, Nussenzweig RS, Eichinger D, Zavala F. Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol Res 1994; 80:16-21.
29. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28:105-14.
30. McCullagh P, Nelder JA. Generalized linear models. Monographs on statistics and applied probability. 2nd ed. New York: Chapman and Hall, 1989.
31. Tibotec. INTELENCE package insert. http://www.intelence-info.com/sites/ default/files/pdf/INTELENCE-Booklet-Package-Insert-hcp.pdf. Accessed 18 March 2011.
32. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001; 184:37-42.
33. Gregory KG, Peters W. The chemotherapy of rodent malaria. IX. Causal prophylaxis. I. A method for demonstrating drug action on exo-erythrocytic stages. Ann Trop Med Parasitol 1970; 64:15-24.
34. Petersen E. In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination. Trans Royal Soc Trop Med Hyg 1987; 81:238-41.
35. Nsanzabana C, Rosenthal PJ. In vitro activity against Plasmodium falciparum of antiretroviral drugs. Antimicrob Agents Chemother 2011; 55:5073-7.
36. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis 2004; 190:1998-2000.
37. Parikh S, Liu J, Sijwali P, Gut J, Goldberg DE, Rosenthal PJ. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob Agents Chemother 2006; 50:2207-9.
38. Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. [published online ahead of print April 26, 2011]. Med Res Rev 2011; doi:10.1002/med.20241.
39. Bumpus NN. Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. Toxicol Appl Pharmacol 2011; 257:227-34.
40. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia AEsplugues JV. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Brit J Pharmacol 2010; 160:2069-84.
41. Patzewitz EM, Wong EH, Muller S. Dissecting the role of glutathione biosynthesis in Plasmodium falciparum. Molecular Microbiology 2012; 83:304-18.
42. Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M, Esplugues JV, Apostolova N. Profile of stress and toxicity gene expression in human hepatic cells treated with efavirenz. Antiviral Research 2012; 94:232-41.
43. Delves M, Plouffe D, Scheurer C, et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Medicine 2012; 9: e1001169.
44. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005; 57:117-45.
45. Mazier D, Renia L, Snounou G. A pre-emptive strike against malaria's stealthy hepatic forms. Nat Rev Drug Discov 2009; 8:854-64.
46. Barker RH Jr., Urgaonkar S, Mazitschek R, et al. Aminoindoles, a novel scaffold with potent activity against Plasmodium falciparum. Antimicrob Agents Chemother 2011; 55:2612-22.
47. Cui L, Zhong Y, Zhu W, Xu Y, Qian X. Selective and sensitive detection and quantification of arylamine N-acetyltransferase 2 by a ratiometric fluorescence probe. Chemical Communications (Cambridge, England) 2010; 46:7121-3.
48. Lim PL, Tan W, Latchoumycandane C, et al. Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol in Vitro 2007; 21:1390-401.
49. AIDSinfo.gov. AIDSinfo drug database, Sulfamethoxazole/Trimetho prim. http://AIDSinfo.nih.gov/drugs/401/sulfamethoxazole-trimethoprim/professional. Accessed June 8 2012.
50. Darlington GJ, Bernhard HP, Miller RA, Ruddle FH. Expression of liver phenotypes in cultured mouse hepatoma cells. J Nat Cancer Inst 1980; 64:809-19.